Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

f Ambit's drug development programs, including the submission of regulatory filings and planned discussions with regulatory bodies, plans regarding future clinical trials of quizartinib and Ambit's other drug candidates, the progress and expected timing of clinical trials, the presentation of data from clinical trials, the clinical benefits to be derived from quizartinib and Ambit's other drug candidates, the regulatory approval path for quizartinib, the strength of Ambit's balance sheet and adequacy of cash on hand, and Ambit's financial guidance.. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as  "plans," "expects," "anticipates," "hopes", "may," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

  Ambit Biosciences CorporationSelected Financial Information Condensed Consolidated Statements of Operations(unaudited, in thou
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... (PRWEB) February 26, 2015 RURO, Inc., ... released FreezerPro® version 6.2 – the latest update to ... reputation is that of a quick and easy method ... With the latest version, RURO engineering has enhanced the ... to move large amounts of sample records. , ...
(Date:2/26/2015)... ANGELES , Feb. 26, 2015 Tauriga ... life sciences company with interests in the natural wellness ... technology, announced today that its products will be featured ... Roth Capital Partners, 27 th Annual Growth Stock ... Carlton, located at 1 Ritz Carlton Drive, ...
(Date:2/26/2015)... February 26, 2015 On Wednesday, February ... building a nationwide Clostridium difficile (C. diff) awareness movement, ... burden study by the Centers for Disease Control & ... almost half a million infections among Americans in a ... homes. , The study also estimates that 29,000 ...
(Date:2/25/2015)... , Feb. 25, 2015 Today, BioMed Realty ... realignment, including a number of promotions and additions to ... company,s strategy to increase shareholder returns through strategic investments ... health care industry and the innovation sector. ... Kent Griffin is leaving his role as President ...
Breaking Biology Technology:RURO Releases FreezerPro® version 6.2 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4BioMed Realty Announces Realignment To Leverage Depth Of Life Science Real Estate Expertise And Increase Shareholder Value 2BioMed Realty Announces Realignment To Leverage Depth Of Life Science Real Estate Expertise And Increase Shareholder Value 3BioMed Realty Announces Realignment To Leverage Depth Of Life Science Real Estate Expertise And Increase Shareholder Value 4
... the first time, Eli Lilly and Company (NYSE: ... grassroots projects across the globe and have their donations matched ... impact of each employee,s charitable contribution. Lilly ... across the world a customized Lilly Global Giving website, where ...
... in the journal Nature Physics , the academics, ... of Manchester in 2004, have revealed more about its ... world are already looking at ways to build devices ... the research from the creators of the material promises ...
... SAN MATEO, Calif., July 22, 2011 NeurogesX, Inc. ... on developing novel pain management therapies, today announced that ... purchase agreement in connection with a private placement to ... standard closing conditions, is expected to receive approximately $20 ...
Cached Biology Technology:Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 2Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 3Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 4Graphene's 'quantum leap' takes electronics a step closer 2NeurogesX, Inc. Announces $20 Million Private Placement 2NeurogesX, Inc. Announces $20 Million Private Placement 3NeurogesX, Inc. Announces $20 Million Private Placement 4
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) ... Global Market Overview" report to their offering. , ... ensure that an individual is who she/he is claiming to ... of a person,s unique physical characteristics, such as fingerprint, hand ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... On September 11, firefighters, police officers and ambulance ... Trade Center complex. They battled to save people from ... and evacuated as many people as they could in ... making their jobs even harder was the problem of ...
... Over the course of a lifetime, the heart pumps ... the order to do this, the muscle fibers of the ... by Dr. Wolfgang Rottbauer, vice chair of the Department of ... A. Katus), has discovered a protein that is responsible for ...
... prescribed by traditional healers in Brazil to treat a range of ... Now for the first time, researchers at Newcastle University have been ... crenata otherwise known as Brazilian mint. , Testing this ... Graciela Rocha was able to show that when prepared as a ...
Cached Biology News:Magic box for mission impossible 2Magic box for mission impossible 3New genetic cause of cardiac failure discovered 2Got a pain? -- Have a cup of Brazilian mint 2
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
... high PCR specificity *High PCR specificity ... enzyme with unique QIAGEN PCR Buffer ... provided by the stringent built-in hot ... Master Mix and simple reaction setup ...
Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
... Thermo Labsystems' Wellwash AC ... twin-strip microplate washer available, and ... sensors for wash, waste and ... shaker and automatic rinsing and ...
Biology Products: